Qianyu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qianyu Wang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Junfeng Du
The Seventh Medical Center, Chinese PLA General Hospital, Beijing, China
5 shared publications Gang Chen
The Seventh Medical Center, Chinese PLA General Hospital, Beijing, China
3 shared publicationsHuiyun Cai
The Seventh Medical Center, Chinese PLA General Hospital, Beijing, China
3 shared publications- Bin Wu
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications Guannan Zhang
Department of General Surgery, Peking Union Medical College Hospital, Beijing, China
2 shared publicationsGuole Lin
Department of General Surgery, Peking Union Medical College Hospital, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (8) , e015376
Tumor stroma-immune interactions shape the immunosuppressive microenvironment and predict response to neoadjuvant chemoradiotherapy plus immunotherapy in rectal cancer
Background: The tumor microenvironment, particularly the tumor stroma, plays a critical role in tumor progression, immune evasion, and therapeutic resistance. However, its interaction with the immune landscape in rectal cancer (RC) remains incompletely understood. This study aimed to comprehensively characterize the stromal-immune ecosystem associated with the tumor stroma ratio (TSR) in RC and to evaluate its clinical and therapeutic relevance. Methods: We analyzed a multicenter cohort of 498 patients with treatment-naïve RC in whom TSR was assessed on H&E-stained sections. Integrative multi-omics analyses were performed, including bulk RNA sequencing (n=118) and single-cell RNA/T-cell receptor (TCR) sequencing (n=10). Key findings were validated by immunohistochemistry (n=114) and multiplex immunofluorescence (n=20). Survival analyses and statistical comparisons were conducted to evaluate clinical associations and treatment responses. Results: High TSR was an independent predictor of unfavorable disease-free survival and cancer-specific survival and was associated with aggressive clinicopathological features. Single-cell analyses revealed that TSR-high tumors exhibited a profoundly immunosuppressive microenvironment, characterized by clonally expanded terminally exhausted CD8 + T cells (CD8 + Tex-CXCL13) and activated CD4 + regulatory T cells (CD4 + Treg-TNFRSF4). Two LRRC15 + cancer-associated fibroblast (CAF) subsets (mCAF-CTHRC1 and mCAF-FAP) were enriched in TSR-high tumors. Among them, mCAF-CTHRC1 was associated with increased Treg abundance and activation features, with predicted interactions with CD4 + Treg-TNFRSF4 cells through the LGALS9–CD44 signaling axis. In addition, SPP1-expressing monocytes (Mon-SPP1) and malignant epithelial cells were prominent in TSR-high tumors and showed a predicted SPP1–CD44 interaction with T-cell subsets, suggesting potential involvement in immunosuppressive stromal-immune interactions. In patients receiving neoadjuvant therapy, pretreatment TSR-low tumors showed improved pathological response and survival outcomes compared with TSR-high tumors. In the neoadjuvant chemoradiotherapy plus immunotherapy cohort, TSR-low tumors were associated with a significantly higher major pathological response rate, whereas pathological complete response showed a non-significant trend in the same direction. Conclusions: High TSR identifies a clinically aggressive subtype of RC characterized by a profoundly immunosuppressive stromal-immune ecosystem enriched for exhausted T cells, immunosuppressive CAF programs, and SPP1-associated stromal-myeloid interactions. These findings highlight LGALS9−, LRRC15−, and SPP1-related stromal-immune pathways as candidate stromal-immune therapeutic vulnerabilities that warrant further mechanistic and preclinical validation.
- 3 August 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (8) , e015376
Open AccessTumor stroma-immune interactions shape the immunosuppressive microenvironment and predict response to neoadjuvant chemoradiotherapy plus immunotherapy in rectal cancer
Background: The tumor microenvironment, particularly the tumor stroma, plays a critical role in tumor progression, immune evasion, and therapeutic resistance. However, its interaction with the immune landscape in rectal cancer (RC) remains incompletely understood. This study aimed to comprehensively characterize the stromal-immune ecosystem associated with the tumor stroma ratio (TSR) in RC and to evaluate its clinical and therapeutic relevance. Methods: We analyzed a multicenter cohort of 498 patients with treatment-naïve RC in whom TSR was assessed on H&E-stained sections. Integrative multi-omics analyses were performed, including bulk RNA sequencing (n=118) and single-cell RNA/T-cell receptor (TCR) sequencing (n=10). Key findings were validated by immunohistochemistry (n=114) and multiplex immunofluorescence (n=20). Survival analyses and statistical comparisons were conducted to evaluate clinical associations and treatment responses. Results: High TSR was an independent predictor of unfavorable disease-free survival and cancer-specific survival and was associated with aggressive clinicopathological features. Single-cell analyses revealed that TSR-high tumors exhibited a profoundly immunosuppressive microenvironment, characterized by clonally expanded terminally exhausted CD8 + T cells (CD8 + Tex-CXCL13) and activated CD4 + regulatory T cells (CD4 + Treg-TNFRSF4). Two LRRC15 + cancer-associated fibroblast (CAF) subsets (mCAF-CTHRC1 and mCAF-FAP) were enriched in TSR-high tumors. Among them, mCAF-CTHRC1 was associated with increased Treg abundance and activation features, with predicted interactions with CD4 + Treg-TNFRSF4 cells through the LGALS9–CD44 signaling axis. In addition, SPP1-expressing monocytes (Mon-SPP1) and malignant epithelial cells were prominent in TSR-high tumors and showed a predicted SPP1–CD44 interaction with T-cell subsets, suggesting potential involvement in immunosuppressive stromal-immune interactions. In patients receiving neoadjuvant therapy, pretreatment TSR-low tumors showed improved pathological response and survival outcomes compared with TSR-high tumors. In the neoadjuvant chemoradiotherapy plus immunotherapy cohort, TSR-low tumors were associated with a significantly higher major pathological response rate, whereas pathological complete response showed a non-significant trend in the same direction. Conclusions: High TSR identifies a clinically aggressive subtype of RC characterized by a profoundly immunosuppressive stromal-immune ecosystem enriched for exhausted T cells, immunosuppressive CAF programs, and SPP1-associated stromal-myeloid interactions. These findings highlight LGALS9−, LRRC15−, and SPP1-related stromal-immune pathways as candidate stromal-immune therapeutic vulnerabilities that warrant further mechanistic and preclinical validation.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-16
Neutrophil Extracellular Traps Predict Prognosis and Neoadjuvant Immunotherapy Response in Gastric Cancer
Purpose: To determine whether neutrophil extracellular trap (NET) predicts prognosis and response to neoadjuvant immunotherapy in gastric cancer (GC) and explore the associated mechanisms. Patients and Methods: Transcriptomic data from a GEO dataset (GSE62254) comprising 300 GC patients were analyzed. Patients were clustered based on 69 predefined NET-related genes (NRGs) summarized in previous studies, and clinical characteristics and immune cell infiltration between clusters were compared. An NRG signature was constructed. Retrospective clinical data and tissue samples from 243 surgically resected GC patients without neoadjuvant therapy and 49 patients receiving neoadjuvant chemotherapy combined with immunotherapy were collected. RNA sequencing, immunohistochemistry, and immunofluorescence were performed to assess NET density and its clinical relevance. Results: Two NET-related subtypes in GC (NT1 and NT2) with distinct clinical features and survival time were identified. A risk model based on five NRGs demonstrated that NT2 had lower risk scores, correlating with favorable outcomes. High NET density was associated with advanced TNM stage and short recurrence-free survival time in the surgery cohort. In the immunotherapy cohort, low pre-treatment NET density correlated with more T cells predicted superior response rates (45.8% vs. 16.0%, P = 0.032) and pathological complete response (29.2% vs. 4.0%, P = 0.023). Conclusion: Low NET density is linked to better prognosis and may identify patients with GC who could benefit from immunotherapy. These findings highlight the important role of NET in GC.
- 1 March 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-16
Open AccessNeutrophil Extracellular Traps Predict Prognosis and Neoadjuvant Immunotherapy Response in Gastric Cancer
Purpose: To determine whether neutrophil extracellular trap (NET) predicts prognosis and response to neoadjuvant immunotherapy in gastric cancer (GC) and explore the associated mechanisms. Patients and Methods: Transcriptomic data from a GEO dataset (GSE62254) comprising 300 GC patients were analyzed. Patients were clustered based on 69 predefined NET-related genes (NRGs) summarized in previous studies, and clinical characteristics and immune cell infiltration between clusters were compared. An NRG signature was constructed. Retrospective clinical data and tissue samples from 243 surgically resected GC patients without neoadjuvant therapy and 49 patients receiving neoadjuvant chemotherapy combined with immunotherapy were collected. RNA sequencing, immunohistochemistry, and immunofluorescence were performed to assess NET density and its clinical relevance. Results: Two NET-related subtypes in GC (NT1 and NT2) with distinct clinical features and survival time were identified. A risk model based on five NRGs demonstrated that NT2 had lower risk scores, correlating with favorable outcomes. High NET density was associated with advanced TNM stage and short recurrence-free survival time in the surgery cohort. In the immunotherapy cohort, low pre-treatment NET density correlated with more T cells predicted superior response rates (45.8% vs. 16.0%, P = 0.032) and pathological complete response (29.2% vs. 4.0%, P = 0.023). Conclusion: Low NET density is linked to better prognosis and may identify patients with GC who could benefit from immunotherapy. These findings highlight the important role of NET in GC.
- Open Access
- 27 November 2024
- Published by Wiley in Cancer Science
- Vol. 116 (2) , 350-366
Pan‐immune‐inflammation value predicts immunotherapy response and reflects local antitumor immune response in rectal cancer
The pan‐immune‐inflammation value reflects the systemic inflammatory response, and tumor‐infiltrating lymphocytes indicate a local immune response in rectal cancer. However, the association between systemic inflammatory response, as indicated by the pan‐immune‐inflammation value, and local immune responses in rectal cancer remains unclear. This study analyzed 915 treatment‐naïve rectal cancer patients from the Peking Union Medical College Hospital and PLA General Hospital (PLAGH) cohorts who underwent radical surgery to investigate the relationship between the pan‐immune‐inflammation value and immune responses. Lower pan‐immune‐inflammation value was significantly associated with improved disease‐free survival and cancer‐specific survival. Multivariate Cox regression models identified the pan‐immune‐inflammation value as an independent prognostic factor. In the PLAGH cohort, patients with low pan‐immune‐inflammation values had higher immune cell levels, activated immune pathways, and increased expression of immune checkpoint genes according to RNA sequencing. Hematoxylin and eosin staining and immunohistochemical analysis revealed that lower pan‐immune‐inflammation value was associated with higher tumor‐infiltrating lymphocyte density, more mature tertiary lymphoid structures, increased CD8+ T cells, and elevated human lymphocyte antigen class I expression. Conversely, patients with high pan‐immune‐inflammation values exhibited pathways linked to tumor progression, such as angiogenesis, epithelial–mesenchymal transition, hypoxia, KRAS signaling, and TGF‐ß signaling. Among patients receiving anti‐PD‐1 therapy, responders had low pre‐ and post‐treatment pan‐immune‐inflammation values. The pan‐immune‐inflammation value is a reliable marker associated with distinct immune microenvironment characteristics and can effectively predict disease‐free survival, cancer‐specific survival, and response to immunotherapy.
- 27 November 2024
- Published by Wiley in Cancer Science
- Vol. 116 (2) , 350-366
Open AccessPan‐immune‐inflammation value predicts immunotherapy response and reflects local antitumor immune response in rectal cancer
The pan‐immune‐inflammation value reflects the systemic inflammatory response, and tumor‐infiltrating lymphocytes indicate a local immune response in rectal cancer. However, the association between systemic inflammatory response, as indicated by the pan‐immune‐inflammation value, and local immune responses in rectal cancer remains unclear. This study analyzed 915 treatment‐naïve rectal cancer patients from the Peking Union Medical College Hospital and PLA General Hospital (PLAGH) cohorts who underwent radical surgery to investigate the relationship between the pan‐immune‐inflammation value and immune responses. Lower pan‐immune‐inflammation value was significantly associated with improved disease‐free survival and cancer‐specific survival. Multivariate Cox regression models identified the pan‐immune‐inflammation value as an independent prognostic factor. In the PLAGH cohort, patients with low pan‐immune‐inflammation values had higher immune cell levels, activated immune pathways, and increased expression of immune checkpoint genes according to RNA sequencing. Hematoxylin and eosin staining and immunohistochemical analysis revealed that lower pan‐immune‐inflammation value was associated with higher tumor‐infiltrating lymphocyte density, more mature tertiary lymphoid structures, increased CD8+ T cells, and elevated human lymphocyte antigen class I expression. Conversely, patients with high pan‐immune‐inflammation values exhibited pathways linked to tumor progression, such as angiogenesis, epithelial–mesenchymal transition, hypoxia, KRAS signaling, and TGF‐ß signaling. Among patients receiving anti‐PD‐1 therapy, responders had low pre‐ and post‐treatment pan‐immune‐inflammation values. The pan‐immune‐inflammation value is a reliable marker associated with distinct immune microenvironment characteristics and can effectively predict disease‐free survival, cancer‐specific survival, and response to immunotherapy.
- Open Access
- 2 March 2024
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-10
Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer
Tertiary lymphoid structure (TLS) contributes to the anti-tumor immune response, and predicts the prognosis of colorectal cancer patients. However, the potential impact of TLS in shaping the immune status of rectal adenocarcinoma, and the intrinsic relationship between TLS and neoadjuvant therapies (neoTx) remain unclear. We performed hematoxylin-eosin staining, immunohistochemical and biomolecular analyses to investigate TLS and tumor-infiltrating lymphocytes (TILs) in 221 neoTx-treated and 242 treatment-naïve locally advanced rectal cancer (LARC) patients. High TLS density was significantly associated with the absence of vascular invasion, a lower neutrophil-to-lymphocyte ratio, increased TLS maturity, a longer recurrence-free survival (RFS) (hazard ratio [HR] 0.2985 95% confidence interval [CI] 0.1894–0.4706, p < 0.0001) and enhanced infiltration of adaptive immune cells. Biomolecular analysis showed that high TLS-score was strongly associated with more infiltration of immune cells and increased activation of immune-related pathways. TLS+ tumors in pre-treatment specimens were associated with a higher proportion of good respond (62.5% vs. 29.8%, p < 0.0002) and pathological complete remission (pCR) (40.0% vs. 11.1%, p < 0.0001), and significantly increased RFS (HR 0.3574 95%CI 0.1489–0.8578 p = 0.0213) compared with TLS- tumors in the neoTx cohort, which was confirmed in GSE119409 and GSE150082. Further studies showed that neoTx significantly reduced TLS density and maturity, and abolished the prognostic value of TLS. Our study illustrates that TLS may have a key role in mediating the T-cell-inflamed tumor microenvironment, which also provides a new direction for neoTx, especially neoadjuvant immunotherapy, in LRAC patients.
- 2 March 2024
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-10
Open AccessTertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer
Tertiary lymphoid structure (TLS) contributes to the anti-tumor immune response, and predicts the prognosis of colorectal cancer patients. However, the potential impact of TLS in shaping the immune status of rectal adenocarcinoma, and the intrinsic relationship between TLS and neoadjuvant therapies (neoTx) remain unclear. We performed hematoxylin-eosin staining, immunohistochemical and biomolecular analyses to investigate TLS and tumor-infiltrating lymphocytes (TILs) in 221 neoTx-treated and 242 treatment-naïve locally advanced rectal cancer (LARC) patients. High TLS density was significantly associated with the absence of vascular invasion, a lower neutrophil-to-lymphocyte ratio, increased TLS maturity, a longer recurrence-free survival (RFS) (hazard ratio [HR] 0.2985 95% confidence interval [CI] 0.1894–0.4706, p < 0.0001) and enhanced infiltration of adaptive immune cells. Biomolecular analysis showed that high TLS-score was strongly associated with more infiltration of immune cells and increased activation of immune-related pathways. TLS+ tumors in pre-treatment specimens were associated with a higher proportion of good respond (62.5% vs. 29.8%, p < 0.0002) and pathological complete remission (pCR) (40.0% vs. 11.1%, p < 0.0001), and significantly increased RFS (HR 0.3574 95%CI 0.1489–0.8578 p = 0.0213) compared with TLS- tumors in the neoTx cohort, which was confirmed in GSE119409 and GSE150082. Further studies showed that neoTx significantly reduced TLS density and maturity, and abolished the prognostic value of TLS. Our study illustrates that TLS may have a key role in mediating the T-cell-inflamed tumor microenvironment, which also provides a new direction for neoTx, especially neoadjuvant immunotherapy, in LRAC patients.
- 1 March 2023
- Published by Wiley in International Journal of Cancer
- Vol. 153 (4) , 709-722
How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
Immunotherapy, especially with immune checkpoint inhibitors (ICIs), has shown advantages in cancer treatment and is a new hope for patients who have failed multiline therapy. However, in colorectal cancer (CRC), the benefit is limited to a small subset of patients with microsatellite instability‐high (MSI‐H) or mismatch repair‐deficient (dMMR) metastatic CRC (mCRC). In addition, 45% to 60% of dMMR/MSI‐H mCRC patients showed primary or acquired resistance to ICIs. This means that these patients may have potential unknown pathways mediating immune escape. Almost all mismatch repair‐proficient (pMMR) or microsatellite‐stable (MSS) mCRC patients do not benefit from ICIs. In this review, we discuss the mechanisms of action of ICIs and their current status in CRC. We then discuss the mechanisms of primary and acquired resistance to ICIs in CRC. Finally, we discuss promising therapeutic strategies to overcome resistance to ICIs in the clinic.
- 1 March 2023
- Published by Wiley in International Journal of Cancer
- Vol. 153 (4) , 709-722
How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
Immunotherapy, especially with immune checkpoint inhibitors (ICIs), has shown advantages in cancer treatment and is a new hope for patients who have failed multiline therapy. However, in colorectal cancer (CRC), the benefit is limited to a small subset of patients with microsatellite instability‐high (MSI‐H) or mismatch repair‐deficient (dMMR) metastatic CRC (mCRC). In addition, 45% to 60% of dMMR/MSI‐H mCRC patients showed primary or acquired resistance to ICIs. This means that these patients may have potential unknown pathways mediating immune escape. Almost all mismatch repair‐proficient (pMMR) or microsatellite‐stable (MSS) mCRC patients do not benefit from ICIs. In this review, we discuss the mechanisms of action of ICIs and their current status in CRC. We then discuss the mechanisms of primary and acquired resistance to ICIs in CRC. Finally, we discuss promising therapeutic strategies to overcome resistance to ICIs in the clinic.
- Top Cited PapersOpen Access
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Colorectal cancer (CRC) is one of the leading causes of death worldwide. The 5-year survival rate is 90% for patients with early CRC, 70% for patients with locally advanced CRC, and 15% for patients with metastatic CRC (mCRC). In fact, most CRC patients are at an advanced stage at the time of diagnosis. Although chemotherapy, molecularly targeted therapy and immunotherapy have significantly improved patient survival, some patients are initially insensitive to these drugs or initially sensitive but quickly become insensitive, and the emergence of such primary and secondary drug resistance is a significant clinical challenge. The most direct cause of resistance is the aberrant anti-tumor drug metabolism, transportation or target. With more in-depth research, it is found that cell death pathways, carcinogenic signals, compensation feedback loop signal pathways and tumor immune microenvironment also play essential roles in the drug resistance mechanism. Here, we assess the current major mechanisms of CRC resistance and describe potential therapeutic interventions.
Top Cited PapersOpen AccessDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Colorectal cancer (CRC) is one of the leading causes of death worldwide. The 5-year survival rate is 90% for patients with early CRC, 70% for patients with locally advanced CRC, and 15% for patients with metastatic CRC (mCRC). In fact, most CRC patients are at an advanced stage at the time of diagnosis. Although chemotherapy, molecularly targeted therapy and immunotherapy have significantly improved patient survival, some patients are initially insensitive to these drugs or initially sensitive but quickly become insensitive, and the emergence of such primary and secondary drug resistance is a significant clinical challenge. The most direct cause of resistance is the aberrant anti-tumor drug metabolism, transportation or target. With more in-depth research, it is found that cell death pathways, carcinogenic signals, compensation feedback loop signal pathways and tumor immune microenvironment also play essential roles in the drug resistance mechanism. Here, we assess the current major mechanisms of CRC resistance and describe potential therapeutic interventions.
- 6 December 2021
- Published by Taylor & Francis in Minimally Invasive Therapy & Allied Technologies
- Vol. 31 (6) , 825-834
Efficacy and safety of over-the-scope clips for colorectal leaks and fistulas: a pooled analysis
The development of laparoscopic technologies and continuous improvements in intracavitary anastomosis technology have significantly reduced the incidence of anastomotic leak (AL) following colorectal surgery. However, AL incidence can significantly increase the duration of patient hospitalization, patient medical expenses, and incidence of mortality. The recently developed over-the-scope clip (OTSC) system has been of increasing clinical interest owing to its ease of use, low complication rates, and high rates of technical and clinical success. The PubMed/Medline, EMBASE, and Cochrane PubMed Library were systematically searched for all studies of OTSC system-mediated closure of ALs and fistulas published from January 2010 to January 2021. Two reviewers independently identified relevant studies based on appropriate inclusion and exclusion criteria. A total of nine studies were included in the present analysis, incorporating 114 patients of whom 107 were treated with an OTSC system. The technical success rate for these patients was 84% (95%CI, 73.5–94.5%; I2 53%), and the clinical success rate was 74.3% (95%CI, 64.4–84.1%; I2 28%) as calculated via a pooled proportion analysis. Complications occurred in two patients. The endoscopic OTSC system is a safe and effective means of treating ALs and fistulas after colorectal surgery.
- 6 December 2021
- Published by Taylor & Francis in Minimally Invasive Therapy & Allied Technologies
- Vol. 31 (6) , 825-834
Efficacy and safety of over-the-scope clips for colorectal leaks and fistulas: a pooled analysis
The development of laparoscopic technologies and continuous improvements in intracavitary anastomosis technology have significantly reduced the incidence of anastomotic leak (AL) following colorectal surgery. However, AL incidence can significantly increase the duration of patient hospitalization, patient medical expenses, and incidence of mortality. The recently developed over-the-scope clip (OTSC) system has been of increasing clinical interest owing to its ease of use, low complication rates, and high rates of technical and clinical success. The PubMed/Medline, EMBASE, and Cochrane PubMed Library were systematically searched for all studies of OTSC system-mediated closure of ALs and fistulas published from January 2010 to January 2021. Two reviewers independently identified relevant studies based on appropriate inclusion and exclusion criteria. A total of nine studies were included in the present analysis, incorporating 114 patients of whom 107 were treated with an OTSC system. The technical success rate for these patients was 84% (95%CI, 73.5–94.5%; I2 53%), and the clinical success rate was 74.3% (95%CI, 64.4–84.1%; I2 28%) as calculated via a pooled proportion analysis. Complications occurred in two patients. The endoscopic OTSC system is a safe and effective means of treating ALs and fistulas after colorectal surgery.